Relief Cardiovascular

With our fundraising activities complete, the team at Relief Cardiovascular is looking to add an Embedded Software Engineer to the team to help us elevate the capabilities of the Relief System to autonomously monitor and treat the million of heart failure patients suffering from persistent congestion. This is an exciting opportunity to join an early-stage venture-backed company that's pioneering a first-of-its-kind transcatheter implant that has the potential to change the way we treat heart failure and redefine what's possible in cardiovascular technology.

With Good Growth Capital's investment in Relief Cardiovascular, the company's Series A is oversubscribed and fully closed. Thank you to everyone who has been a part of this journey. The team is more excited than ever to be moving this technology forward into its clinical study. Thank you Samuel Scofield and Amy Salzhauer for being fantastic partners through this process. Relief Cardiovascular is thrilled to have the team at Good Growth Capital be a part of this journey.

“A lot of times with heart failure, a huge portion of the issue is that interplay between the heart and the kidneys. We've done so much on the heart side addressing all of this, but it seems like we're missing that other half of the equation. And that’s what led us to start really focusing on the kidneys What's great with Relief is that we're actually improving blood flow through the kidneys. [It] presents a unique opportunity, where we may be able to enhance diuresis without beating up the kidneys in the process.” Watch Alexander Cooper, MBA, Founder and CEO of Relief Cardiovascular, explain how renal vein pressure contributes to congestion in heart failure patients, the gap in current solutions, and Relief Cardio’s unique solution to improve patient outcomes. ?? ?? ?? For more information on the company, please read their $12M Series A announcement: https://lnkd.in/gkSAp2cC

More than 6 million Americans have had their life expectancy reduced by 10 years due to congestive heart failure. For many of these patients, heart failure management is incredibly burdensome and minimally effective, and, in some cases, surgical treatments are necessary to extend their life and to make modest gains in quality of life. While at Edwards Lifesciences and CardiAQ, Alexander Cooper, MBA spent his time leading development teams to aiming to treat heart failure in the valves. During his tenure, he and his teams contributed to the development of the world’s first transcatheter mitral valve replacement system and the world’s first transcatheter tricuspid valve replacement system. After a few years of traveling domestically and internationally to help clinicians implant devices in patients, Alex observed that many of these patients were returning to the hospital with significant congestion (fluid buildup) and difficulty breathing, indicating additional causes of congestion beyond the heart valves. Emotionally rocked by this revelation, Alex began intense research and he discovered medical literature that pointed to pressure in the renal veins as significant factor in the fluid buildup. Armed with this insight, Alex founded Relief Cardiovascular in 2022 with a mission to reimagine the way we treat congestive heart failure. Relief Cardiovascular’s smart transcatheter implant is designed to modulate and to monitor renal vein pressure, providing a new approach to heart failure fluid management. Recently, I visited Alex and his team at their offices in Orange County, and 30 mins prior to our conversation, he successfully closed their $12M Series A round co-led by Broadview Ventures Inc and Advent Life Sciences! It’s my honor and privilege to share my conversation with Alexander Cooper, MBA, Founder and CEO of Relief Cardiovascular. During our full conversation, Alex and I discussed: - Alex’s Background - Heart Failure and Fluid Buildup - The Gap in Current Solutions? - Relief Cardiovascular’s Smart Transcatheter Implant? - Why Cardiologists Are Excited About Relief Cardiovascular - Data and Artificial Intelligence? - Relief Cardiovascular’s Team - Near-Term Roadmap - Alex’s Vision for Relief Cardiovascular Watch Alexander Cooper, MBA detail the design of Relief Cardiovascular’s smart transcatheter implant, the unique health data it collects, and the potential for future artificial intelligence applications that leverage this data to improve clinical outcomes. ?? ?? ?? For more information on the company, please read their $12M Series A announcement: https://lnkd.in/gkSAp2cC Website: https://lnkd.in/gM2RH5GD

We’re excited to announce the closing of a $12M Series A financing, co-led by Broadview Ventures Inc and Advent Life Sciences. This funding will support the advancement of the Relief System into its first-in-human study. The Relief System is the world’s first transcatheter implant to both monitor and modulate renal vein pressures, offering a novel solution for managing fluid in heart failure patients – particularly for the millions of heart failure patients with diuretic resistance. Additionally, we’re honored to welcome Shahzad Malik and Maria Berkman, MD, MBA to our Board of Directors, who will provide key insights and guidance as we move into the clinic and beyond. #HeartFailure #MedTech #SeriesA #Innovation #Cardiovascular #ReliefCardiovascular

The team at Relief Cardiovascular will be in Frankfurt for CSI D-HF December 13th-14th and is looking forward to an incredible program of innovative therapies in heart failure and collaborating with clinical partners CSI congress

Relief Cardiovascular is proud to collaborate with the team at Cardiovascular Research Foundation's Skirball Center for Innovation. Today, the team is excited to complete some of its most pivotal preclinical work to-date.

The team at Relief Cardiovascular will be in Washington DC for TCT Sunday 10/27-10/30 and is looking forward to collaborating with existing and new clinical partners as we approach our first-in-human clinical experience with our transcatheter smart implant for heart failure. Cardiovascular Research Foundation #tct

Our CEO, Alexander Cooper, MBA, was recently featured in MedTech MAESTROS, where he discusses the company's vision of intelligent implants that respond to hemodynamics to monitor and manage heart failure. As the company approaches its first-in-human experience, it is excited by the opportunity to make an impact to the millions of patients living with heart failure. "Whoever can best integrate data and therapy in the most frictionless fashion is going to have the largest impact on heart failure."

Thank you, The MedTech Conference, MedTech Innovator, and Lisa Carmel for an excellent panel discussing the future of cardiovascular devices. Excited to see what's next for Relief Cardiovascular and the incredible work from Gilbert Madrid (Laguna Tech) and Judi O' Malley (Spiorad Medical Limited )